Inventiva S.A.
Inventiva S.A. is a France-based biopharmaceutical company focused on the discovery and clinical development of oral small-molecule therapies. Its principal development program is lanifibranor, a drug candidate being advanced for metabolic and fibrotic diseases, especially MASH. The company is publicly listed in France and the United States.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2022–2025
Liiketoiminta
Osuus liikevaihdostaThe company's lead clinical candidate for metabolic and fibrotic diseases, including MASH.
Early-stage discovery, preclinical work, and additional research programs around new therapeutics.
Research, development, and commercialization partnerships supporting program advancement.
Asiakkaat
Inventiva does not sell a broad commercial product portfolio; its immediate counterparties are clinical investigators, research partners, regulators, and capital providers that support development of its drug candidates. If lanifibranor is successfully approved and commercialized, customers would expand to physicians, hospitals, and patients in the relevant therapeutic areas.
Trial sites, investigators, and CRO-style collaborators that execute studies and generate development data.
Health agencies that review clinical results and determine whether product candidates can advance to approval.
Specialists and physicians who would prescribe lanifibranor if approved for metabolic liver disease.
Patients with MASH or related fibrotic/metabolic conditions who would be treated with the approved therapy.
Companies or institutions that co-develop, finance, or support the pipeline through partnerships.
Strategia
Inventiva’s strategy is centered on advancing lanifibranor through pivotal clinical development, seeking regulatory approval, and preparing for possible commercialization. It also depends on partnerships and financing to support long development timelines typical of biotechnology programs.
Late-stage clinical data is the key gate to regulatory review and eventual commercialization.
Approval is required to convert the pipeline into a commercial product business.
Clinical development is capital intensive and partnerships can extend runway and de-risk commercialization.
Maantiede
Inventiva is headquartered in France and is listed on Euronext Paris and Nasdaq in the United States. Its operations are centered on European and U.S. drug development activities, with clinical and regulatory work tied to global trial sites and potential commercialization markets.
Riskit
Inventiva is exposed to clinical trial failure, regulatory setbacks, and the need to continuously fund a long and capital-intensive development path. Because lanifibranor is the core value driver, any negative data, delays, or financing shortfalls could materially impair the company’s ability to continue development or commercialize its pipeline.
- Financing and going-concern pressureVaikutus: KriittinenTodennäköisyys: Korkea
The business requires external capital before product sales can fund operations.
Kohdistuu: Operating cash needs
- Lanifibranor clinical failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company's valuation and future commercialization depend heavily on one lead candidate.
Kohdistuu: Lead asset concentration
- Regulatory delay or non-approvalVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even positive data may not be sufficient for an approval filing or label expansion.
Kohdistuu: MASH development program
- Patent and collateral encumbranceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Debt financing has granted lenders security interests over key assets, including patents.
Kohdistuu: Intellectual property
- Partnering and execution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Delays or disagreements with collaborators can slow clinical and commercial plans.
Kohdistuu: Development partnerships
Kirjanpito
Harkinnanvaraiset erätClinical and preclinical work is expensed as incurred, driving operating loss presentation.
Vaikutus: Affects operating results and comparability across periods
Funding needs and future product revenue uncertainty require explicit assessment.
Vaikutus: Can materially affect disclosures and investor perception
Borrowings, warrants, and related security packages may involve valuation and classification judgments.
Vaikutus: Can affect liabilities, equity, and finance costs
Pipeline assets and patents depend on clinical success and future commercial prospects.
Vaikutus: Could trigger large non-cash charges if value declines
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Enanta Pharmaceuticals, Inc
ENTA · Pharmaceutical Preparations
Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology.
Innoviva, Inc.
INVA · Pharmaceutical Preparations
Lexicon Pharmaceuticals, Inc
LXRX · Pharmaceutical Preparations
Lexicon Pharmaceuticals is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines.
BioInvent International
BINV · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
Nanobiotix S.A.
NBTX · Pharmaceutical Preparations
Päivitetty: 28.9.2026